Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2005Website:
http://www.mtem.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:59:50 GMTDividend
Analysts recommendations
Institutional Ownership
MTEM Latest News
AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) for cancer and immune-mediated disease, today provided an update on its clinical-stage programs.
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates.
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What type of business is Molecular Templates?
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
What sector is Molecular Templates in?
Molecular Templates is in the Healthcare sector
What industry is Molecular Templates in?
Molecular Templates is in the Biotechnology industry
What country is Molecular Templates from?
Molecular Templates is headquartered in United States
When did Molecular Templates go public?
Molecular Templates initial public offering (IPO) was on 04 February 2005
What is Molecular Templates website?
https://www.mtem.com
Is Molecular Templates in the S&P 500?
No, Molecular Templates is not included in the S&P 500 index
Is Molecular Templates in the NASDAQ 100?
No, Molecular Templates is not included in the NASDAQ 100 index
Is Molecular Templates in the Dow Jones?
No, Molecular Templates is not included in the Dow Jones index
When was Molecular Templates the previous earnings report?
No data
When does Molecular Templates earnings report?
The next expected earnings date for Molecular Templates is 28 March 2025